GSA Capital Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

GSA Capital Partners’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,897	Closed	-$394K	–	2041
2025 Q3	$394K	Sell	3,897 -2,200	-36%	-$204K	0.03%	1015
2025 Q2	$385K	Buy	6,097 +1,028	+20%	+$62.9K	0.03%	1108
2025 Q1	$269K	Buy	+5,069	New	+$281K	0.02%	1224
2023 Q4	–	Sell	-16,465	Closed	-$377K	–	1869
2023 Q3	$377K	Sell	16,465 -52,099	-76%	-$1.17M	0.03%	961
2023 Q2	$1.13M	Buy	+68,564	New	+$1.24M	0.11%	245
2023 Q1	–	Sell	-7,451	Closed	-$217K	–	1878
2022 Q4	$217K	Sell	7,451 -1,641	-18%	-$42.2K	0.03%	1138
2022 Q3	$223K	Sell	9,092 -14,055	-61%	-$261K	0.03%	1141
2022 Q2	$96K	Buy	+23,147	New	+$127K	0.01%	1226

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GSA Capital Partners's RYTM Position: Q4 2025 in Review

GSA Capital Partners sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2025, closing a stake of 3,897 shares — an estimated $394K sold.

GSA Capital Partners first reported a position in RYTM in Q2 2022 and held it in 8 quarters. The position peaked at $1.13M in Q2 2023. 279 funds tracked by Wall St. Rank hold RYTM as of Q4 2025.

GSA Capital Partners reported no remaining Rhythm Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
GSA Capital Partners sold 3,897 Rhythm Pharmaceuticals shares in Q4 2025, an estimated $394K.
GSA Capital Partners first reported a position in Rhythm Pharmaceuticals in Q2 2022 and held it in 8 quarters.
GSA Capital Partners's Rhythm Pharmaceuticals position peaked at $1.13M in Q2 2023.
279 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.